NO874796L - Hybridomcellelinjer som produserer monoklonale antistoffer som reagerer med mucinepitoper. - Google Patents

Hybridomcellelinjer som produserer monoklonale antistoffer som reagerer med mucinepitoper.

Info

Publication number
NO874796L
NO874796L NO87874796A NO874796A NO874796L NO 874796 L NO874796 L NO 874796L NO 87874796 A NO87874796 A NO 87874796A NO 874796 A NO874796 A NO 874796A NO 874796 L NO874796 L NO 874796L
Authority
NO
Norway
Prior art keywords
cell lines
monoclonal antibodies
producing monoclonal
pitopes
hybridom
Prior art date
Application number
NO87874796A
Other languages
English (en)
Other versions
NO175944C (no
NO175944B (no
NO874796D0 (no
Inventor
Peter S Linsley
Diane Horn
Joseph P Brown
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26801637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO874796(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncogen filed Critical Oncogen
Publication of NO874796D0 publication Critical patent/NO874796D0/no
Publication of NO874796L publication Critical patent/NO874796L/no
Publication of NO175944B publication Critical patent/NO175944B/no
Publication of NO175944C publication Critical patent/NO175944C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO874796A 1986-11-19 1987-11-18 Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse NO175944C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93278186A 1986-11-19 1986-11-19
US10451187A 1987-10-08 1987-10-08

Publications (4)

Publication Number Publication Date
NO874796D0 NO874796D0 (no) 1987-11-18
NO874796L true NO874796L (no) 1988-05-20
NO175944B NO175944B (no) 1994-09-26
NO175944C NO175944C (no) 1995-01-04

Family

ID=26801637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO874796A NO175944C (no) 1986-11-19 1987-11-18 Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse

Country Status (17)

Country Link
US (1) US5849876A (no)
EP (1) EP0268279B2 (no)
JP (1) JP2597372B2 (no)
KR (1) KR900007951B1 (no)
AT (1) ATE130029T1 (no)
AU (1) AU613590B2 (no)
CA (1) CA1340815C (no)
DE (1) DE3751585T3 (no)
DK (1) DK175635B1 (no)
ES (1) ES2080717T5 (no)
GR (1) GR3018093T3 (no)
HK (1) HK1007766A1 (no)
IE (1) IE71154B1 (no)
IL (1) IL84475A (no)
NO (1) NO175944C (no)
NZ (1) NZ222509A (no)
PT (1) PT86180B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
JPH02255097A (ja) * 1989-03-29 1990-10-15 Ikuo Yamashina 単クローン抗体ｎｎｙ１２８
JPH06503177A (ja) * 1991-06-26 1994-04-07 ザ　バイオメンブレイン　インスティテュート 抗―炭水化物抗体の組合せを利用しての肺癌の早期診断
FR2697088B1 (fr) * 1992-10-15 1997-06-27 Lacassagne Centre Antoine Anticorps monoclonaux pour le diagnostic différentiel de cancers épithéliaux dans des épanchements séreux, hybridomes les secrétant et kit de diagnostic.
EP0695760A1 (en) * 1994-08-05 1996-02-07 F. Hoffmann-La Roche Ag Novel tumor marker for lung cancer
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
JP2002518347A (ja) 1998-06-15 2002-06-25 アルタレックス コーポレイション 前立腺癌治療のための免疫療法組成物および方法
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
MXPA02010869A (es) * 2000-05-08 2003-04-14 Medarex Inc Anticuerpos monoclonales humanos para celulas dendriticas.
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
EP2287198A3 (en) 2002-03-13 2011-05-25 Biogen Idec MA Inc. Anti-alpha V beta 6 antibodies
AU2003295502A1 (en) 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
US7175846B2 (en) * 2003-01-21 2007-02-13 Arius Research Inc. Cancerous disease modifying antibodies
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US20050027106A1 (en) * 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US20050255041A1 (en) * 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
US7394210B2 (en) * 2004-09-29 2008-07-01 Tir Technology Lp System and method for controlling luminaires
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
CA2628837C (en) * 2005-11-07 2018-11-27 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CN101675158A (zh) * 2006-02-24 2010-03-17 阿里乌斯研究公司 癌性疾病调节抗体
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007095745A1 (en) 2006-02-24 2007-08-30 Arius Research Inc. Cancerous disease modifying antibody 141205-02
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
KR20090059166A (ko) * 2006-09-28 2009-06-10 센토코 오르토 바이오테크 인코포레이티드 단일클론 항체 생산에서 애주번트로서의 프로스타글란딘 ｅ2 (ｐｇｅ2)
CN101535471B (zh) * 2006-11-13 2011-06-29 霍夫曼-拉罗奇有限公司 修饰癌症病的抗体180706-02
KR20090088879A (ko) * 2006-11-13 2009-08-20 에프. 호프만-라 로슈 아게 암 질환 조절 항체
WO2008058381A1 (en) * 2006-11-13 2008-05-22 Arius Research Inc. Cancerous disease modifying antibodies
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
KR20090114454A (ko) * 2007-03-26 2009-11-03 에프. 호프만-라 로슈 아게 하이브리도마 세포주 ａｒ５１ａ６３０.３ 에 의해 생성된 암 질환 조절 항체 ０１０２０７－０１.
CN101688183A (zh) * 2007-05-07 2010-03-31 霍夫曼-拉罗奇有限公司 减轻癌性疾病的抗体
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
WO2009124381A1 (en) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
JP2011520923A (ja) * 2008-05-19 2011-07-21 武田薬品工業株式会社 細胞傷害性抗癌モノクローナル抗体
EP2313437A1 (en) * 2008-07-17 2011-04-27 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP3397592B1 (en) * 2015-12-30 2022-11-09 Colgate-Palmolive Company Mucin coated silica for bacterial aggregation
CN110317273A (zh) * 2018-03-30 2019-10-11 积水医疗株式会社 与dupan-2抗原特异性反应的单克隆抗体及其制造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650756A (en) * 1981-08-31 1987-03-17 Sloan Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human renal cancer
US4584268A (en) * 1981-10-13 1986-04-22 Ceriani Roberto Luis Method and compositions for carcinoma diagnosis
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
GB2131830A (en) * 1982-12-10 1984-06-27 Ludwig Inst Cancer Res Monoclonal antibody for use against breast cancer
US4678747A (en) * 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
DE3483054D1 (de) * 1983-03-04 1990-10-04 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4643971A (en) * 1983-03-11 1987-02-17 Sloan-Kettering Institute Monoclonal antibodies to human bladder and ureter cancers and method
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4935344A (en) * 1984-04-30 1990-06-19 Sloan-Kettering Institute For Cancer Research Method for characterizing types of renal carcinoma and prognosis
EP0160446B1 (en) * 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Breast tumor-associated antigen and monoclonal antibodies specific thereto
US4960716A (en) * 1984-05-01 1990-10-02 Ciba Corning Diagnostics Corp. Monoclonal antibodies specific for 330 KD breast tumor antigen and assay using said monoclonal antibodies
US4683200A (en) * 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
NZ212419A (en) * 1984-06-25 1988-08-30 Mucan Diagnostics Pty Ltd In vitro diagnostic test for detecting cancer cells producing mucin antigens
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
IL76877A (en) * 1984-11-02 1991-11-21 Oncogen Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
US4628032A (en) * 1984-12-05 1986-12-09 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cytoplasmic antigen
EP0184369B1 (en) * 1984-12-05 1992-04-01 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
US4814275A (en) * 1985-05-13 1989-03-21 E.I. Dupont De Nemours And Company Monoclonal hybridoma antibody specific for a human epithelial antigen
US4863854A (en) * 1985-08-12 1989-09-05 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to mucin-like human differentiation antigens
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4803169A (en) † 1986-02-05 1989-02-07 Cetus Corporation Assay for human breast cancer
WO1988005054A1 (en) † 1987-01-07 1988-07-14 Imperial Cancer Research Technology Limited Probe

Also Published As

Publication number Publication date
IL84475A (en) 1992-06-21
EP0268279B2 (en) 2003-12-03
KR900007951B1 (ko) 1990-10-23
CA1340815C (en) 1999-11-09
NO175944C (no) 1995-01-04
EP0268279A2 (en) 1988-05-25
EP0268279B1 (en) 1995-11-08
NO175944B (no) 1994-09-26
JP2597372B2 (ja) 1997-04-02
GR3018093T3 (en) 1996-02-29
AU8099487A (en) 1988-06-09
IE71154B1 (en) 1997-01-29
ES2080717T5 (es) 2004-07-16
KR880006358A (ko) 1988-07-22
IE873110L (en) 1988-05-19
DE3751585T2 (de) 1996-04-25
US5849876A (en) 1998-12-15
PT86180A (en) 1987-12-01
DK606287D0 (da) 1987-11-18
DE3751585T3 (de) 2004-08-05
ATE130029T1 (de) 1995-11-15
DK606287A (da) 1988-05-20
EP0268279A3 (en) 1991-07-03
NZ222509A (en) 1993-03-26
AU613590B2 (en) 1991-08-08
HK1007766A1 (en) 1999-04-23
IL84475A0 (en) 1988-04-29
DK175635B1 (da) 2004-12-27
JPS63279784A (ja) 1988-11-16
DE3751585D1 (de) 1995-12-14
ES2080717T3 (es) 1996-02-16
PT86180B (pt) 1990-11-07
NO874796D0 (no) 1987-11-18

Similar Documents

Publication Publication Date Title
NO874796L (no) Hybridomcellelinjer som produserer monoklonale antistoffer som reagerer med mucinepitoper.
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
EP0118365A3 (en) Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
ES8609731A1 (es) Un metodo para diagnosticar una condicion neoplastica en un hospedante mamifero
ZA833686B (en) Human human hybridomas for cervical carcinoma
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
DK0759032T3 (da) Isolerede peptider, der er afledt fra MAGE-3, og som komplekserer med HLA-A2-molekyler, samt anvendelse heraf
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
EP0232871A3 (en) Human monoclonal antibody, hybridoma producing the same and its use
DK0454782T3 (da) Cancer-beslægtet haptaglobin (Hpr.)
ES8800604A1 (es) Un metodo para producir anticuerpos monoclonales
EP0297930A3 (en) Monoclonal antibodies
DE59209776D1 (de) Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
EP0278160A3 (en) Human monoclonal anti cancer antibodies, hybridoma cell lines producing them and their uses
GR3007245T3 (no)
EP0243058A3 (en) A novel tumor associated antigen

Legal Events

Date Code Title Description
MK1K Patent expired